175
References
1. Miller JW, Walsh AW, Kramer M, Hasan T, Michaud N, Flotte
TJ, Haimovici R, Gragoudas ES. Photodynamic therapy of exper-
imental choroidal neovascularization using lipoprotein-delivered
benzoporphyrin. Arch Ophthalmol 1995; 113 (6): 810-8.
2. Kramer M, Miller JW, Michaud N, Moulton RS, Hasan T, Flotte
TJ, Gragoudas ES. Liposomal benzoporphyrin derivative verte-
porfin photodynamic therapy. Selective treatment of choroidal
neovascularization in monkeys. Ophthalmology 1996; 103 (3):
427-38.
3. Henderson BW, Dougherty TJ. How does photodynamic therapy
work? Photochem Photobiol 1992; 55 (1): 145-57.
4. Schmidt-Erfurth U, Sacu S; Early Retreatment Study Group.
Randomized multicenter trial of more intense and standard early
verteporfin treatment of neovascular age-related macular degen-
eration. Ophthalmology 2008; 115 (1): 134-40.
5. Photodynamic therapy of subfoveal choroidal neovascularization
in age-related macular degeneration with verteporfin: one-year re-
sults of 2 randomized clinical trials--TAP report. Treatment of age-
related macular degeneration with photodynamic therapy (TAP)
Study Group. Arch Ophthalmol 1999; 117 (10): 1329-45.
6. Bressler NM; Treatment of Age-Related Macular Degeneration
with Photodynamic Therapy (TAP) Study Group. Photodynamic
therapy of subfoveal choroidal neovascularization in age-related
macular degeneration with verteporfin: two-year results of 2 ran-
domized clinical trials-tap report 2. Arch Ophthalmol 2001; 119
(2): 198-207.
7. Bressler NM, Arnold J, Benchaboune M, Blumenkranz MS, Fish
GE, Gragoudas ES, Lewis H, Schmidt-Erfurth U, Slakter JS,
Bressler SB, Manos K, Hao Y, Hayes L, Koester J, Reaves A, Strong
HA; Treatment of Age-Related Macular Degeneration with Pho-
todynamic Therapy (TAP) Study Group. Verteporfin therapy of
subfoveal choroidal neovascularization in patients with age-related
macular degeneration: additional information regarding baseline
lesion composition’s impact on vision outcomes-TAP report No.
3. Arch Ophthalmol 2002; 120 (11): 1443-54.
8. Blumenkranz MS, Bressler NM, Bressler SB, Donati G, Fish GE,
Haynes LA, Lewis H, Miller JW, Monés JM, Potter MJ, Pournaras
C, Reaves A, Rosenfeld PJ, Schachat AP, Schmidt-Erfurth U, Sick-
enburg M, Singerman LJ, Slakter JS, Strong A, Vannier S; Treat-
ment of Age-Related Macular Degeneration with Photodynamic
Therapy (TAP) Study Group. Verteporfin therapy for subfoveal
choroidal neovascularization in age-related macular degeneration:
three-year results of an open-label extension of 2 randomized clini-
cal trials--TAP Report no. 5. Arch Ophthalmol 2002; 120 (10):
1307-14.
9. Bressler NM, Bressler SB, Haynes LA, Hao Y, Kaiser PK, Miller
JW, Naor J, Potter MJ, Pournaras CJ, Reaves A, Rosenfeld PJ,
Schmidt-Erfurth U, Slakter JS, Strong A, Vannier S. Verteporfin
therapy for subfoveal choroidal neovascularization in age-related
macular degeneration: four-year results of an open-label extension
of 2 randomized clinical trials: TAP Report No. 7. Arch Ophthal-
mol 2005; 123 (9): 1283-5.
10. Blinder KJ, Bradley S, Bressler NM, Bressler SB, Donati G, Hao
Y, Ma C, Menchini U, Miller J, Potter MJ, Pournaras C, Reaves A,
Rosenfeld PJ, Strong HA, Stur M, Su XY, Virgili G; Treatment of
Age-related Macular Degeneration with Photodynamic Therapy
study group; Verteporfin in Photodynamic Therapy study group.
Effect of lesion size, visual acuity, and lesion composition on visual
acuity change with and without verteporfin therapy for choroidal
neovascularization secondary to age-related macular degeneration:
TAP and VIP report no. 1. Am J Ophthalmol 2003; 136 (3): 407-
18.
11. Verteporfin in Photodynamic Therapy (VIP) Study Group. Verte-
porfin therapy of subfoveal choroidal neovascularization in age-
related macular degeneration: two year results of a randomized
clinical trial including lesions with occult with no classic choroidal
neovascularization. — Verteporfin in photodynamic therapy re-
port 2. Am J Ophthalmol 2001; 131: 541-60.
12. Azab M, Boyer DS, Bressler NM, Bressler SB, Cihelkova I, Hao
Y, Immonen I, Lim JI, Menchini U, Naor J, Potter MJ, Reaves A,
Rosenfeld PJ, Slakter JS, Soucek P, Strong HA, Wenkstern A, Su
XY, Yang YC; Visudyne in Minimally Classic Choroidal Neovas-
cularization Study Group. Verteporfin therapy of subfoveal mini-
mally classic choroidal neovascularization in age-related macular
degeneration: 2-year results of a randomized clinical trial. Arch
Ophthalmol 2005; 123 (4): 448-57.
13. Cruess AF, Zlateva G, Pleil AM, Wirostko B. Photodynamic
therapy with verteporfin in age-related macular degeneration: a
systematic review of efficacy, safety, treatment modifications and
pharmacoeconomic properties. Acta Ophthalmol 2009; 87 (2):
118-32.
14. Azab M, Benchaboune M, Blinder KJ, Bressler NM, Bressler SB,
Gragoudas ES, Fish GE, Hao Y, Haynes L, Lim JI, Menchini U,
Miller JW, Mones J, Potter MJ, Reaves A, Rosenfeld PJ, Strong A,
Su XY, Slakter JS, Schmidt-Erfurth U, Sorenson JA; Treatment of
Age-Related Macular Degeneration with Photodynamic Therapy
(TAP) Study Group; Verteporfin in Photodynamic Therapy (VIP)
Study Group. Verteporfin therapy of subfoveal choroidal neovas-
cularization in age-related macular degeneration: meta-analysis of
2-year safety results in three randomized clinical trials: Treatment
Of Age-Related Macular Degeneration With Photodynamic Ther-
apy and Verteporfin In Photodynamic Therapy Study Report no.
4. Retina 2004; 24 (1): 1-12.
15. Kaiser PK. Treatment of Age-Related Macular Degeneration with
Photodynamic Therapy (TAP) Study Group. Verteporfin therapy
of subfoveal choroidal neovascularization in age-related macular
degeneration: 5-year results of two randomized clinical trials with
an open-label extension: TAP report no. 8. Graefes Arch Clin Exp
Ophthalmol 2006; 244 (9): 1132-42.
16. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev
T; ANCHOR Study Group. Ranibizumab versus verteporfin
photodynamic therapy for neovascular age-related macular degen-
eration: Two-year results of the ANCHOR study. Ophthalmology
2009; 116 (1): 57-65.e5.
17. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim
RY, Sy JP, Schneider S; ANCHOR Study Group. Ranibizumab
versus verteporfin for neovascular age-related macular degenera-
tion. N Engl J Med 2006; 355 (14): 1432-44.
18. Bressler NM, Chang TS, Fine JT, Dolan CM, Ward J; Anti-VEGF
Antibody for the Treatment of Predominantly Classic Choroidal
Neovascularization in Age-Related Macular Degeneration (AN-
CHOR) Research Group. Improved vision-related function after
ranibizumab vs photodynamic therapy: a randomized clinical trial.
Arch Ophthalmol 2009; 127 (1): 13-21.
19. Antoszyk AN, Tuomi L, Chung CY, Singh A; FOCUS Study
Group. Ranibizumab combined with verteporfin photodynamic
Photodynamic Therapy
